Oxybutynin Chloride Tablet
Product Images NDC 43063-851

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Oxybutynin Chloride (NDC 43063-851). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

43063851 Label (43063851)

43063851 Label (43063851)
Each tablet contains Oxybutynin Chloride, USP 5 mg. The recommended dosage for adults is one tablet two to four times a day, and for pediatric patients, it is one tablet two to three times a day. The medication is dispensed in a tight, light-resistant container and should be stored at 20°C to 25°C (68°F to 77°F). It is important to keep the medicine out of the reach of children. The medication is manufactured by NDOC and marketed and packaged by PD-Rx Pharmaceuticals. The package contains 90 tablets.*
FDA Label Image

Structural Formula (Figure 1 Structure)

Structural Formula (Figure 1 Structure)
FDA Label Image

Table 1 (Figure 2 Table1)

Table 1 (Figure 2 Table1)
This text provides information about the pharmacokinetic parameters of R- and S-Oxybutynin. It includes measurements of G (ng/ml), Toa (1), AUC (ng=h/mL), and UGy (ng/ehiml) for both R-Oxybutynin and S-Oxybutynin. The values for these parameters are given in parentheses for each molecule.*
FDA Label Image

Figure 1 (Figure 3 Figure1)

Figure 1 (Figure 3 Figure1)
FDA Label Image

Table 2 (Figure 4 Table2)

Table 2 (Figure 4 Table2)
FDA Label Image

Figure 2 (Figure 5 Figure2)

Figure 2 (Figure 5 Figure2)
FDA Label Image

Table 3 (Figure 6 Table3)

Table 3 (Figure 6 Table3)
Oxybutynin Chloride is a medication that may cause several adverse events in different body systems. The medication may cause urinary tract infection, insomnia, nervousness, dizziness, somnolence, headache, blurred vision, dry mouth, constipation, nausea, dyspepsia, urinary hesitation, and urinary retention. The percentages of these events vary from 5% to 714%.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.